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Background. Mannose-binding lectin (MBL) is a serum lectin involved in innate immune response. Low serum
MBL concentration may constitute a risk factor for infection in patients receiving myelosuppressive chemotherapy.
Methods. We conducted a prospective, observational study that assessed MBL concentration as a risk factor
for infection in patients with hematological malignancy who were hospitalized to undergo at least 1 chemotherapy
cycle. MBL deficiency was defined using an algorithm that considered the serum MBL concentration and the MBL
genotype. The primary end point was the ratio of duration of febrile neutropenia to the duration of neutropenia.
Secondary end points included the incidence of severe infection (e.g., sepsis, pneumonia, bacteremia, and invasive
fungal infection). Logistic regression analysis was conducted, and Fisher’s exact test was used to analyze binary
outcomes, and Kaplan-Meier estimates and log rank tests were used for time-to-event variables.
Results. We analyzed 255 patients who received 569 cycles of chemotherapy. The median duration of neutro-
penia per cycle was 7 days (interquartile range, 0–13 days). Sixty-two patients (24%) were found to have MBL
deficiency. Febrile neutropenia occurred at least once in 200 patients. No difference in the primary outcome was
seen. The incidence of severe infection was higher among MBL-deficient patients than among non–MBL-deficient
patients (1.96 vs. 1.34 cases per 100 days for analysis of all patients [ ] and 1.85 vs. 0.94 cases per 100Pp .008
days excluding patients with acute leukemia [ ]).P ! .001
Conclusions. MBL deficiency does not predispose adults with hematological cancer to more-frequent or more-
prolonged febrile episodes during myelosuppressive chemotherapy, but MBL-deficient patients have a greater
number of severe infections and experience their first severe infection earlier, compared with nondeficient patients.
Mannose-binding lectin (MBL) is a serum protein im-
portant in the innate immunity system [1, 2]. MBL
initiates the complement cascade [3] through the bind-
ing of cellular membrane constituent sugars present on
the surface of pathogens. Serum MBL concentrations
vary between individuals by a factor up to a 1000, rang-
ing from !5 to 15000 ng/mL, because of genetic mu-
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tations within the gene and its promoters [4, 5]. In the
literature, the incidence of the O/O genotype ranges
from 3% to 16%, depending on the ethnic group stud-
ied [6].
We tested the hypothesis, generated by previous stud-
ies [7–10], that patients with hematological cancer who
are MBL deficient have a higher risk of developing in-
fectious complications when receiving myelosuppres-




Adult patients (age, 116 years) with hematological ma-
lignancy who were undergoing chemotherapy were
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No. (%) of fully eligible cyclesa 569 136 (23) 433 (76)
Duration of neutropenia per cycle, median days (IQR) 7 (0–13) 6 (0–13) 7 (0–13)
No. (%) of cycles involving growth factors [95% CI] 359 (63) [59–67] 82 (60) 277 (64)
No. (%) of cycles involving prophylactic antimicrobial use [95% CI]
All 386 (68) [64–72] 92 (68) 294 (68)
Antibacterialsb 229 (40) [36–44] 50 (37) 179 (41)
Antiviralsc 274 (48) [44–52] 66 (49) 208 (48)
Antifungalsd 266 (47) [43–51] 62 (46) 204 (47)
No. (%) of cycles involving a cytarabine-containing regimen [95% CI] 237 (42) [38–46] 50 187
Reason for chemotherapy, no. (%) of cycles [95% CI]
Transplantation
All 168 (30) [26–33] 43 (32) [24–40] 125 (29) [25–33]
Autograft 129 34 95
Allograft 25 6 19
Leukemia
Induction 38 8 30
Consolidation, intensification, or other 109 16 93
Reinduction 19 2 17
Reason other than leukemia
First-line 88 23 65
Subsequent line 315 87 228
NOTE. IQR, interquartile range; MBL, mannose-binding lectin.
a There were 587 registered cycles (139 among MBL-deficient patients and 448 among non–MBL-deficient patients). Of those, 18 had a restricted eligibility
(3 among MBL-deficient patients and 15 among non–MBL-deficient patients); these 18 cycles were included in all analyses that considered cumulative cycles.
The reason for restricted eligibility was ongoing fever or receipt of antibiotic treatment for a previously registered cycle. There was no significant difference in
the distribution of MBL deficiency for the cycles of restricted eligibility, compared with fully eligible cycles.
b Ciprofloxacin, 227 cycles; trimethoprim-sulfamethoxazole, 47 cycles; various agents for the rest.
c In all cases, the agent used was acyclovir.
d Fluconazole, 209 cycles; itraconazole, 125 cycles; amphotericin B aerosols, 75 cycles; nystatin, 2 cycles; and voriconazole, 2 cycles.
eligible. Patients must have been afebrile and not receiving
antimicrobial treatment for an ongoing infection at the time
of enrollment in the study. The study was conducted at 3 uni-
versity hospitals. All patients who were scheduled to undergo
myelosuppressive chemotherapy for hematological malignan-
cies were sequentially offered enrollment in the study. Patients
could have received prior chemotherapy before enrollment.
Written informed consent was obtained from all participants.
The study protocol was approved by each institution’s ethics
committee.
Definitions
Neutropenia was defined as an absolute neutrophil count of
!500 cells/mL. The duration of neutropenia was measured from
the first occurrence of a neutrophil count of !500 cells/mL
until permanent recovery (neutrophil counts, 500 cells/mL).
Fever was defined as a temperature of 38.5C recorded on at
least 1 occasion or as a temperature of 38C noted on 2
occasions during a 12-h period. Febrile neutropenia was defined
as fever that occurred during neutropenia, regardless of what
may have been the cause of the fever. For patients who ex-
perienced fever, the date of defervescence was defined as the
first day in a 5-day period in which the patient’s temperature
was !38C. Severe infection was defined as the presence of
pneumonia, septicemia, invasive fungal infection, or sepsis.
Sepsis was considered to be present when 2 of the following
criteria were present: temperature, 138C or !36C; heart rate,
1110 beats/min; respiratory rate, 120 breaths/min; or partial
pressure of carbon dioxide, !32 mm Hg. Sepsis had to be
associated with a microbiologically or clinically documented
infection. Mucositis of grade 3 or 4 that occurred during fever
of unknown origin was considered to represent a documented
infection. Pneumonia had to be documented by the presence
of a pulmonary infiltrate noted on a chest radiograph or chest
CT. Septicemia was defined as the presence of clinical signs or
symptoms of infection accompanied by a microbiologically
documented clinical infection and by the isolation of a bac-
terium or fungus in a blood specimen, with the exception of
some pathogens (e.g., Staphylococcus epidermidis). These path-
ogens were considered to be contaminant pathogens when they
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Table 2. Distribution of the genotypes and mean concentrations















YA/YA 58 31 51 3731 (3312–4150)
XA/YA 54 29 46 2508 (2128–2888)
YA/O 37 20 35 743 (544–943)
XA/XA 15 8 13 1131 (634–1627)
XA/O 12 6 11 317 (0–720)
O/O 11 6 … …
Total 187 100 … …
Missing 68 … … …
Total 255 … … …
NOTE. Three point mutations in exon 1 of the MBL2 gene are strongly
associated with low MBL concentrations. These 3 structural variants are
named B, C, and D for mutations on codons 54, 57, and 52 respectively. The
normal allele is called A; other variants are called O.
occurred in only 1 culture bottle with positive results only or
in patients for whom 1 blood specimen was used in 2 culture
bottles; thus, they were not relevant in the definition of sep-
ticemia. A minimum of 2 positive results for culture bottles
that included 2 different blood specimen sets were to be taken
into account. Invasive fungal infections were classified as prob-
able or proven on the basis of European Organization for Re-
search and Treatment of Cancer–Mycosis Study Group criteria
[11].
End Points
The ratio of the duration of febrile neutropenia (calculated as
the number of febrile neutropenic days) to the duration of
neutropenia (calculated as the number of neutropenic days)
was the primary end point. This end point covers the most
important determinant of initiation of or change in treatment
for patients undergoing myelosuppressive therapy. It also takes
into account the fact that the duration of neutropenia influ-
ences the frequency, severity, and outcome of infection [12]. It
is sometimes difficult to determine the precise cause of fever
in the context of chemotherapy and neutropenia; therefore, all
reported days of fever were taken into consideration, even if
the fever was finally determined to be unrelated to an infectious
problem in our classification of documentation of infection.
The secondary end points included the time to a first event
and the following events: occurrence of fever (including all
causes of fever), clinically or microbiologically documented in-
fectious episodes occurring during neutropenia, severe infec-
tions (as defined above), septicemia, and documented bacter-
emia, independent of the presence or absence of neutropenia.
Observation Period
Patients were enrolled during the period from December 2001
through December 2003. Patients were observed from the first
day of each cycle of chemotherapy administration after en-
rollment until recovery from neutropenia. The maximum du-
ration of follow-up was 45 days for patients with protracted
neutropenia.
Laboratory Tests
All analyses were performed blindly by NatImmune (Copen-
hagen, Denmark). Clinicians were blinded to all results of the
analyses.
MBL plasma concentration. Plasma samples were obtained
for assessment of the mbl2 genotype and/or to determine the
plasma MBL level; samples had to be obtained on day 1 of
chemotherapy or during the 3 days preceding chemotherapy.
MBL concentration was measured using a time-resolved im-
munofluorometric assay [13].
Genotyping. MBL genotyping was performed as described
elsewhere [14, 15] using a real-time PCR assay on a LightCycler
(Roche Applied Sciences). This assay detects a single-nucleotide
polymorphism by monitoring the temperature-dependent hy-
bridization of probes to single-stranded DNA. Detection of the
hybridization was performed using fluorescence resonance en-
ergy transfer.
Assessment of MBL deficiency. MBL concentration was al-
ways determined in the absence of fever or infection before
chemotherapy. When possible, the MBL concentration was de-
termined before the first cycle of chemotherapy. However, for
a few patients, the MBL concentration was determined prior
to a subsequent cycle of chemotherapy or after the completion
of chemotherapy. MBL deficiency was defined as an MBL con-
centration of !500 ng/mL [10].
Statistical Analysis
Descriptive analysis was performed using frequency tabulations
for categorical variables and summary parameters for contin-
uous variables. Analysis of variance was performed for serum
MBL levels on the basis of genotype.
For assessment of the risk of infection in relation to MBL
status, analyses were performed using the patient as the analysis
unit (with 2 end points: counts of events per 100 days of follow-
up and time to the first event) or the first chemotherapy cycle
as an analysis unit. Several statistical models were used to fit
the data and to compare the groups of MBL-deficient and non–
MBL-deficient patients (the Mann-Whitney U test was used
for comparing the ratio of febrile neutropenic days to neutro-
penic days, and the x2 test or Fisher’s exact test was used for
comparing binary variables). Counts of events were analyzed
using Poisson regression models, and time-to-event variables
were analyzed using both Kaplan-Meier estimates and Cox re-
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No. of eligible patients 62 193
Age, median years (range) 55 (20–77) 52 (19–80)
No. (%) of male patients 40 (64) 112 (58)
Median time from diagnosis to registration (range) 168 days (0–16 years) 201 days (0–18 years)
No. (%) of registered chemotherapy cycles per patient
1 34 (55) 98 (51)
2 12 (19) 38 (20)
3 5 (8) 24 (12)
4 3 (5) 9 (5)
5 3 (5) 11 (6)
15 5 (8) 13 (7)
Underlying cancer, proportion (%) of patients
Acute leukemia 16/62 (26) 62/193 (32)
Myeloma 16/62 (26) 39/193 (20)
High-grade lymphoma 10/62 (16) 31/193 (16)
Intermediate-grade lymphoma 10/62 (16) 13/193 (7)
Hodgkin disease 2/62 (3) 14/193 (7)
Chronic leukemia 4/62 (6) 11/193 (6)
Myelodysplasic syndrome 4/62 (6) 11/193 (6)
Low-grade lymphoma 0/62 (0) 9/193 (5)
Leukemia not otherwise specified 0/62 (0) 2/193 (1)
Polycythemia vera 0/62 (0) 1/193 (!1)
Duration of neutropenia per patient, median days (IQR) 9 (5–16) 9 (5–15)
NOTE. A total of 255 patients were eligible from among the 282 enrolled patients. IQR, interquartile range.
a Data are for 587 cycles.
gression models. Regression coefficients were estimated using
the maximum likelihood method and are reported with 95%
CIs. All reported P values are 2-tailed and nominal. For cor-
recting for multiplicity (i.e., febrile neutropenia and docu-
mented and severe infections analyzed in terms of counts of
events and time to the first event with 2 subgroups), we applied
Bonferroni’s conservative method; therefore, shouldP ! .004
be used to define significance, to keep the overall risk of at
least 1 false-positive result to 5%. Secondary analysis was re-
stricted to the period of neutropenia throughout all cycles for
each patient and for subgroup analysis that excluded patients
with acute leukemia.
RESULTS
Characteristics of patients and chemotherapy cycles. Two
hundred eighty-two patients, who underwent a total of 688
cycles of chemotherapy, were enrolled in the study. On the 255
eligible patients, the following assessments were possible: 210
patients were evaluated on the basis of an adequate serum
sample at the first eligible cycle, 25 patients were evaluated on
the basis of an adequate serum sample at a subsequent eligible
cycle, 16 patients were assessed for genotype only (15 patients
with the A/A or A/O genotype were classified as non–MBL
deficient, and 1 patient with the O/O genotype was classified
as MBL deficient), and 4 patients were assessed using all avail-
able plasma MBL levels.
Overall, 62 (24%) of 255 patients were determined to be
MBL deficient. The median number of available plasma MBL
levels for the 255 eligible patients was 9 (range, 0–57). Of the
187 patients with available genotypes, 23 (12%) had XA/O or
O/O genotypes (table 1).
Of 688 cycles of chemotherapy administered to 282 sequen-
tial patients, 53 cycles were unassessable (i.e., no serum, ge-
notype, or outcome information was available), and 48 were
ineligible. Reasons for ineligibility were as follows: for 43 cycles,
the patients had ongoing fever or were receiving ongoing an-
tibiotic therapy for a previous infection at the time of enroll-
ment (these 43 episodes involved 36 patients, 31 of whom had
acute leukemia), 4 cycles involved patients who were eligible
for the study but who did not consent to participate, and 1
cycle involved a patient who received an injection of contam-
inated stem cells and was thus considered to have a baseline
infection. There were 569 fully eligible cycles, and 18 cycles had
to be included in the analysis despite the occurrence of baseline
infection or fever because they involved patients who were
already included in the study. Therefore, 587 cycles involving
Table 4. Univariate analysis of incidence of infectious complication.
Variable
MBL Status







All patients (n p 255)
Documented infection
No. of events 117 353 …
Rate of event per 100 days 3.30 2.80 1.17 (0.96–1.45) .12
Severe infection
No. of events 69 166 …
Rate of event per 100 days 1.96 1.34 1.46 (1.11–1.94) .008
Septicemiab
No. of events 27 88 …
Rate of event per 100 days 0.77 0.71 1.08 (0.70–1.66) .73
Sepsisb
No. of events 30 77 …
Rate of event per 100 days 0.85 0.56 1.37 (0.90–2.09) .14
Pneumonia
No. of events 25 49 …
Rate of event per 100 days 0.71 0.39 1.80 (1.11–2.91) .02
Patients with nonacute leukemia (n p 177)
No. of patients 46 131 …
Documented infection
No. of events 85 171 …
Rate of event per 100 days 3.11 2.21 1.40 (1.08–1.82) .009
Severe infection
No. of events 50 72 …
Rate of event per 100 days 1.85 0.94 1.97 (1.37–2.83) !.001
Septicemiab
No. of events 19 27 …
Rate of event per 100 days 0.70 0.35 2.00 (1.11–3.59) .02
Sepsisb
No. of events 21 33 …
Rate of event per 100 days 0.78 0.50 1.80 (1.04–3.12) .03
Pneumonia
No. of events 17 26 …
Rate of event per 100 days 0.63 0.34 1.85 (1.01–3.42) !.05
All patients, considering only the period of
neutropenia during follow-up (n p
241)
No. of patients 60 181 …
Documented infection
No. of events 93 276 …
Rate of event per 100 days 7.15 6.51 1.10 (0.87–1.39) .43
Severe infection
No. of events 58 146 …
Rate of event per 100 days 4.46 3.44 1.30 (0.96–1.76) .10
Patients with nonacute leukemia, consider-
ing only the period of neutropenia
during follow-up (n p 165)
No. of patients 44 121 …
Severe infection
No. of events 39 60 …
Rate of event per 100 days 4.99 2.96 1.69 (1.13–2.53) .01
NOTE. MBL, mannose-binding lectin; RR, relative risk.
a RR is for the estimated increase in the rate of events in MBL-deficient patients.
b Defined in the Definitions subsection of Methods.
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Table 5. Time to the development of the first infectious complication.
Group, outcome
Time to the development of
the first infectious complication,
median days





All patients (n p 255)
Fever 11 12 1.15 (0.84–1.58) .36
Febrile neutropenia 12 13 1.12 (0.81–1.54) .49
Severe infection
All 20 54 1.50 (1.04–2.16) .03
Bacteremia 74 93 1.34 (0.85–2.13) .20
Sepsis 121 NR 1.39 (0.85–2.26) .19
Pneumonia 118 162 1.51 (0.89–2.56) .13
Excluding patients with acute leukemia (n p 177)
Fever 12 12 1.15 (0.79–1.68) .47
Febrile neutropenia 12 13 1.08 (0.73–1.60) .69
Severe infection
All 21 84 1.79 (1.14–2.80) .01
Bacteremia 90 190 2.08 (1.13–3.85) .02
Sepsis 165 NR 1.81 (0.98–3.34) .05
Pneumonia 131 NR 1.44 (0.73–2.83) .29
NOTE. Statistically significant variables are shown in boldface font. HR, hazard ratio; MBL, mannose-binding lectin; NR, number
of events was insufficient to calculate a median value.
a Determined using the log rank test.
255 patients were analyzed. A total of 168 intensification cycles
(30% of fully eligible cycles; 95% CI, 26%–33% of fully eligible
cycles) were performed in preparation for transplantation, as
follows: autologous stem cell transplantations, 129 cycles; al-
lograft transplantations, 25 cycles; and minitransplantations, 13
cycles (1 transplantation was ultimately not performed).
Follow-up of the patient was not completed until recovery
from neutropenia for 16 of 136 cycles in the MBL-deficient
group versus 53 of 433 cycles in the non–MBL-deficient group
( ); this was most commonly the reason when patientsPp 1
without fever or infection were discharged from the hospital
with neutropenia, when a new chemotherapy cycle was started,
or when the patient died. Baseline characteristics were similar
for patients and cycles for the MBL-deficient and non–MBL-
deficient groups (tables 2 and 3).
Influence of MBL concentration on infection. The primary
end point (i.e., the ratio of the number of febrile neutropenic
days to the number of neutropenic days) was similar in MBL-
deficient patients and non–MBL-deficient patients. The count
of severe infections was found to be higher in MBL-deficient
patients (table 4), and those severe infections developed earlier
in MBL-deficient patients (table 5); in patients without acute
leukemia, these associations were stronger. The rate of docu-
mented infection was not statistically different when the entire
population was considered. Univariate analysis of the time to
the first severe infection for the entire patient population
( ) revealed a shorter time to the first severe infectionnp 255
for MBL-deficient patients than for non–MBL-deficient pa-
tients (20 vs. 54 days; hazard ratio, 1.5; , determinedPp .01
by log rank test) (figure 1A).
Multivariate analyses were performed to adjust for factors
known to affect the risk of infection. These factors were as
follows: (1) use of antibiotic prophylaxis, administration of
growth factors, or both; (2) diagnosis of a hematologic malig-
nancy other than myeloma and lymphoma (e.g., acute leukemia
and other diagnoses); and (3) diabetes. Only factors that were
found to be significant in a univariate analysis were included
in the multivariate model.
Multivariate analysis was performed to determine the rate
of severe infection, the rate of documented infection, and the
time to first severe infection (these were the 3 outcomes that
had a significant result on univariate analysis and that were
thought to be most relevant to infection in cases of neutro-
penia). For the 3 outcomes in the multivariate analysis, an
increased risk was present in MBL-deficient patients, compared
with non–MBL-deficient patients (table 6).
Analysis on the first cycles only. We restricted the analysis
to the first cycle of chemotherapy included for each of the 255
patients. The median duration of follow-up for the first cycle
was 25 days (range, 0–45 days; interquartile range, 17–37 days).
In the overall per-patient analysis, there were 141 patients
who developed at least 1 severe infection. Of these patients,
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Figure 1. Kaplan-Meier estimates of time to first severe infection
among patients with mannose-binding lectin (MBL) deficiency. Severe
infection was defined as pneumonia, invasive fungal infection, septicemia,
and/or sepsis associated with an infection. A, Analysis of all 255 patients
for time to first severe infection, showing a shorter time to event for
MBL-deficient patients than for non–MBL-deficient patients (median, 20
vs. 54 days; hazard ratio, 1.50; 95% CI, 1.04–2.16; , by log rankPp .01
analysis). B, Analysis of all 241 patients having developed neutropenia
for time to first severe infection, showing that the time to first severe
infection during neutropenia was shorter in MBL-deficient patients than
in non–MBL-deficient patients (median, of 10 vs. 21 days ; ).Pp .05
Sixty patients were MBL deficient, and 127 patients developed at least
1 severe infection during neutropenia. C, Analysis excluding 165 patients
with acute myeloid leukemia for time to first severe infection, showing
that the time to first severe infection during neutropenia was shorter in
44 MBL-deficient patients than in 121 non–MBL-deficient patients (me-
dian, 35 vs. 8 days; ).Pp .01
104 developed this first severe infection during the follow-up
period for the first cycle. Analysis of the influence of MBL
deficiency on the time to severe infection revealed that the 75th
percentile for time to infection development during follow-up
was 10 days among MBL-deficient patients, whereas it was 12
days for non–MBL-deficient patients (hazard ratio, 1.52; 95%
CI, 1.00–2.31; ). The number of severe infections wasPp .05
not significantly linked to the MBL deficiency status (relative
risk, 1.38; 95% CI, 0.96–2.00; ). On bivariate analysis,Pp .08
the results were similar after adjustment for antibiotic pro-
phylaxis (adjusted hazard ratio, 1.53; 95% CI, 1.00–2.33;
, by stratified log rank test) and administration ofPp .05
growth factors (adjusted hazard ratio, 1.55; 95% CI, 1.02–2.36;
, by stratified log rank test).Pp .04
MBL concentration, neutropenia, and infectious
complications. Analysis was performed by looking at the in-
cidence of severe infections that occurred during neutropenia.
Fourteen patients who never developed neutropenia were ex-
cluded from this analysis. Among the remaining 241 patients,
60 were MBL deficient. One hundred twenty-seven patients
developed at least 1 severe infection during the period of
neutropenia.
The rate of severe infection was higher in the analysis that
examined the period of neutropenia than in the analysis that
examined the total duration of follow-up. The rate of severe
infection was similar in MBL-deficient and non–MBL-deficient
patients when analyzing the entire population. When we ex-
cluded patients with acute leukemia, the rate of severe infection
in MBL-deficient patients was higher than the rate in non-
MBL-deficient patients ( ) (table 4).P ! .05
The time to the first severe infection during neutropenia was
shorter in MBL-deficient patients than in non–MBL-deficient
patients (10 vs. 21 days; ) in the entire populationPp .05
(figure 1B). The time to the first severe infection in 165 neu-
tropenic patients who did not have leukemia (44 of whom were
MBL deficient) was shorter in MBL-deficient patients than in
non–MBL-deficient patients (8 vs. 35 days; ) (figurePp .01
1C).
DISCUSSION
The present study did not reveal a difference in the primary
outcome (i.e., the effect of the duration of febrile neutropenia
on the number of days of neutropenia). However, a higher risk
of severe infection was noted for patients with hematological
malignancies who were receiving chemotherapy and who had
low MBL concentrations, compared with patients with a normal
MBL concentration. These severe infections occurred earlier in
patients who were MBL-deficient.
A recent retrospective study suggested that a microbiologi-
cally confirmed systemic or disseminated infection is more
common among patients with cancer who have a MBL defi-
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Table 6. Multivariate analysis of the number of infectious complications and the time to severe
infection.
Variable, covariate Adjusted risk (95% CI)a Adjusted HR (95% CI) P
Documented infection
MBL deficiency 1.30 (1.05–1.61) … .02
Use of growth factors alone 1.73 (1.18–1.79) … !.001
Acute leukemia 1.73 (1.41–2.13) … !.001
Leukemia other than acute leukemia
and myeloma/lymphoma 1.40 (1.04–1.87) … .03
Absence of diabetes 0.74 (0.57–0.97) … .03
Severe infection
MBL deficiency 1.70 (1.28–2.27) … !.001
Use of growth factors alone 2.06 (1.41–3.03) … !.001
Acute leukemia 1.89 (1.44–2.48) … !.001
Absence of diabetes 0.60 (0.42–0.85) … .005
Time to severe infection
MBL deficiency … 1.77 (1.22–2.57) .003
Use of growth factors alone … 2.77 (1.69–4.54) !.001
No acute leukemia … 0.49 (0.35–0.71) !.001
NOTE. HR, hazard ratio; MBL, mannose-binding lectin.
a Estimated increase in the rate among MBL-deficient patients.
ciency and who are undergoing high-dose chemotherapy and
autologous peripheral blood stem cell transplantation [16].
These results are similar to the conclusions of our study.
Various end points have been used to investigate the infection
risk in patients with hematological malignancies who are un-
dergoing chemotherapy. Studies that measured the incidence
of fever as an end point did not find an association with MBL
deficiency [17, 18], which is consistent with the results of the
present study, in which febrile episodes and their duration did
not vary on the basis of MBL status. However, one study of
children with malignancies did find an association between the
duration of febrile neutropenic episodes and MBL deficiency
[19]. Fifty-five percent of the subjects in that study had acute
lymphocytic leukemia, and 9% had neuroblastoma; this differs
from the population evaluated in the present study
In 2001, a retrospective study of 54 adult patients who re-
ceived treatment for hematological cancer, including a few cases
of acute leukemia (13%), suggested that there was a greater
number of MBL-deficient patients among subjects with major
infections (13 of 16) than among those with minor infections
(11 of 38) [10]. Kilpatrick et al. [18] found no relationship
between MBL levels and chemotherapy-related infection. In
that retrospective study, 128 adult patients who underwent che-
motherapy for hematological cancer were evaluated. These pa-
tients had similar types of diseases and received similar treat-
ments, as did patients in the present study. The population was
divided into 4 clinical subgroups on the basis of type of in-
fection and fever and into 4 categories on the basis of MBL
concentration. When all 4 subgroups were analyzed together,
no significant association was found between MBL concentra-
tion and chemotherapy-related infection. The frequency of pa-
tients with a very low level of MBL deficiency (MBL level, !100
mg/L, as determined by ELISA) was higher among subjects with
major infection (e.g., pneumonia and/or bacteremia) than
among subjects who showed no sign of infection. Although the
data are not directly comparable (i.e., the cutoff values and
methodologies are different), these results differ from the results
of the study by Peterslund et al. [10], who found a strong
association between MBL concentration and chemotherapy-
related infection when a higher MBL cutoff value (!500 mg/L,
as determined by time-resolved immunofluorometric assay)
was used.
Both studies evaluated a small number of patients. None of
the studies adjusted for potential confounding risks for infec-
tion, such as the use of granulocyte colony-stimulating factor
or antibiotic prophylaxis, as was done in the present study.
The results of the studies discussed above, despite their lim-
itations, are compatible with our findings: MBL concentration
influences the risk of infection, but the magnitude of the risk
decreases in the context of prolonged neutropenia. This is con-
sistent with the results of the study by Bergmann et al. [20].
Two factors should be considered when evaluating the as-
sociation between MBL concentration and the risk of infection
in patients with acute leukemia. First, the duration of neutro-
penia was longer in patients with acute leukemia than in other
patients (14.5 vs. 5 days; ). Second, there may haveP ! .001
been an enrollment bias, because patients with acute leukemia
and an ongoing fever or infection were excluded at the study’s
start. Severe immunosuppression in patients with acute mye-
locytic leukemia who are undergoing chemotherapy may reduce
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the ability to demonstrate the protective effects of MBL in these
patients. Indeed, few functional scavenger cells are present in
patients with acute leukemia, which may reduce the impact of
the opsonization deficit that results from MBL deficiency.
The present study is, to our knowledge, the largest study to
have evaluated the risk of infectious complications associated
with MBL deficiency to have been published to date, and our
results should be added to the growing evidence that a low
MBL concentration increases the risk of severe infection in
patients undergoing chemotherapy. In conclusion, the signifi-
cantly increased risk of severe infection in MBL-deficient pa-
tients found in this study is relevant and strongly supports the
evaluation of the use of MBL replacement therapy for this
population.
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